膜杰作
Star Staining
抗体来源（Source）
Biotinylated FMC63 scFv, Fc, Avitag is a chimeric monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which combines the variable region of a mouse monoclonal antibody with human IgG1 constant domain.
特异性（Specificity）
Specifically recognizes the antigen-recognition domain of CD19-derived CARs.
应用（Application）
Flow Cytometry (Evaluation of Anti-CD19 (FMC63 scFv) ADA Expression).
纯度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20 to -70°C for 12 months in lyophilized state from date of receipt;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳（SDS-PAGE）
Biotinylated FMC63 scFv, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-MALS
The purity of Biotinylated FMC63 scFv, Fc,Avitag (Cat. No. CD9-BV4324b) is more than 90% and the molecular weight of this protein is around 100-120 kDa verified by SEC-MALS.
Report
活性（Bioactivity）-ELISA
Immobilized Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a at 1 μg/mL, add increasing concentrations of Rabbit Anti-Mouse FMC63 Polyclonal Antibody (Cat. No. FM3-S93) and then add Biotinylated FMC63 scFv, Fc,Avitag (Cat. No. CD9-BV4324b) at 2 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 78 ng/mL (QC tested).
Protocol
背景（Background）
FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.
